Companies Structure Therapeutics Inc.
Structure Therapeutics (GPCR): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Structure Therapeutics Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers1st pct.Of 1 peer CEOs
CEO pay, last three years
- $7,390,911FY2023
- $5,738,850FY2024
- $8,429,887FY2025
CEO total pay was $8,429,887 in fiscal 2025, up from $5,738,850 in fiscal 2024.
FY2025: salary $672,094 · bonus $0 · stock awards $2,387,996 · option awards $4,846,926
Executives and directors
Blai Coll · Chief Medical OfficerRaymond Stevens · CEOJun Yoon · CFOXichen Lin · Chief Scientific OfficerYingli Ma · CTOAngus C. Russell · Independent DirectorDaniel G. Welch · Chair of the BoardEric Dobmeier · Independent DirectorJoanne Waldstreicher, M.D · Independent DirectorSharon Tetlow · Independent DirectorTed W. Love, M.D · Independent Director
Frequently asked questions
Who was the highest-paid executive at Structure Therapeutics Inc. in fiscal 2025?
As disclosed, Raymond Stevens (Chief Executive Officer and Director) was the highest-paid executive at Structure Therapeutics Inc. in fiscal 2025, with total compensation of $8,429,887.
How does Structure Therapeutics Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Raymond Stevens's total compensation ranked at the 1st percentile of Structure Therapeutics Inc.'s disclosed peer group.
What is Structure Therapeutics Inc.'s CEO-to-median employee pay ratio?
As disclosed, Structure Therapeutics Inc.'s CEO-to-median employee pay ratio was 29:1.
How did shareholders vote on Structure Therapeutics Inc.'s executive compensation?
As disclosed, 96.24% of shareholders supported Structure Therapeutics Inc.'s executive compensation in the latest say-on-pay vote.
How much does Structure Therapeutics Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Structure Therapeutics Inc. reported total board compensation of $561,500 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Raymond Stevens | $672,094 | $0 | $2,387,996 | $4,846,926 | $508,871 | $0 | $14,000 | $8,429,887 |
| Chief Executive Officer and Director | ||||||||
| Jun Yoon | 530,530 | 0 | 1,193,998 | 2,423,463 | 309,075 | 0 | 10,529 | 4,467,595 |
| Chief Financial Officer | ||||||||
| Blai Coll | 492,813 | 0 | 820,866 | 1,666,117 | 253,151 | 0 | 14,000 | 3,246,947 |
| Chief Medical Officer | ||||||||
| Xichen Lin | 505,313 | 0 | 567,150 | 1,151,143 | 257,103 | 0 | 0 | 2,480,709 |
| Chief Scientific Officer | ||||||||
| Yingli Ma | 429,768 | 0 | 447,734 | 908,788 | 212,592 | 0 | 0 | 1,998,882 |
| Chief Technology Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Raymond Stevens | $8,429,887 | $5,738,850 | $7,390,911 | ↑ +2,691,037 |
| Jun Yoon | 4,467,595 | — | 3,674,770 | — |
| Blai Coll | 3,246,947 | 3,451,040 | — | ↓ −204,093 |
| Xichen Lin | 2,480,709 | 3,690,766 | — | ↓ −1,210,057 |
| Yingli Ma | 1,998,882 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
In designing our executive compensation program, the Compensation Committee and the Board are guided by the following philosophy and objectives: Attract and Retain Talent: Deliver competitive compensation at levels that attract, motivate and retain talented executives who contribute to the success of our business; Pay for Performance: Award compensation that motivates and rewards short- and long-term individual and company performance while discouraging excessive risk-taking; Alignment with Strategy: Provide incentives that motivate and reward the achievement of performance goals that directly correlate to the execution of our strategy and the enhancement of shareholder value, as well as to facilitate executive retention; and Alignment with Shareholders: Align our NEOs interests with those of our shareholders.
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Blai Coll | OPTION | 2025-03-15 | — | — | 284,241 | — | $1,666,117 |
| Jun Yoon | OPTION | 2025-03-15 | — | — | 413,445 | — | 2,423,463 |
| Jun Yoon | RSU | 2025-03-15 | — | — | 170,166 | — | 1,193,998 |
| Xichen Lin | RSU | 2025-03-15 | — | — | 80,829 | — | 567,150 |
| Raymond Stevens | RSU | 2025-03-15 | — | — | 340,332 | — | 2,387,996 |
| Xichen Lin | OPTION | 2025-03-15 | — | — | 196,386 | — | 1,151,143 |
| Blai Coll | RSU | 2025-03-15 | — | — | 116,988 | — | 820,866 |
| Raymond Stevens | OPTION | 2025-03-15 | — | — | 826,890 | — | 4,846,926 |
| Yingli Ma | RSU | 2025-03-15 | — | — | 63,810 | — | 447,734 |
| Yingli Ma | OPTION | 2025-03-15 | — | — | 155,040 | — | 908,788 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Blai Coll | $820,866 | $0 | $1,666,117 | 0.0% |
| Jun Yoon | 1,193,998 | 0 | 2,423,463 | 0.0% |
| Xichen Lin | 567,150 | 0 | 1,151,143 | 0.0% |
| Raymond Stevens | 2,387,996 | 0 | 4,846,926 | 0.0% |
| Yingli Ma | 447,734 | 0 | 908,788 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Blai Coll | RSU | 3,996 | — | $92,641 |
| Blai Coll | Option | 5,760 | 2.79 | — |
| Blai Coll | RSU | 9,000 | — | 208,650 |
| Yingli Ma | RSU | 12,231 | — | 283,555 |
| Blai Coll | Option | 18,564 | 11.75 | — |
| Jun Yoon | RSU | 19,803 | — | 459,100 |
| Yingli Ma | RSU | 27,549 | — | 638,678 |
| Xichen Lin | RSU | 28,539 | — | 661,629 |
| Blai Coll | Option | 31,275 | 7.66 | — |
| Jun Yoon | RSU | 44,604 | — | 1,034,069 |
| Raymond Stevens | RSU | 44,850 | — | 1,039,773 |
| Yingli Ma | Option | 51,468 | 11.75 | — |
| Yingli Ma | RSU | 63,810 | — | 1,479,329 |
| Xichen Lin | RSU | 64,281 | — | 1,490,248 |
| Blai Coll | RSU | 67,950 | — | 1,575,308 |
| Blai Coll | Option | 76,314 | 12.75 | — |
| Xichen Lin | RSU | 80,829 | — | 1,873,886 |
| Jun Yoon | Option | 83,328 | 11.75 | — |
| Jun Yoon | Option | 100,000 | 1.21 | — |
| Xichen Lin | Option | 100,000 | 1.21 | — |
| Raymond Stevens | RSU | 101,013 | — | 2,341,818 |
| Blai Coll | RSU | 116,988 | — | 2,712,172 |
| Xichen Lin | Option | 120,087 | 11.75 | — |
| Yingli Ma | Option | 155,040 | 7.02 | — |
| Jun Yoon | RSU | 170,166 | — | 3,945,015 |
| Raymond Stevens | Option | 188,712 | 11.75 | — |
| Xichen Lin | Option | 196,386 | 7.02 | — |
| Jun Yoon | Option | 218,775 | 5 | — |
| Blai Coll | Option | 284,241 | 7.02 | — |
| Raymond Stevens | RSU | 340,332 | — | 7,890,030 |
| Yingli Ma | Option | 400,000 | 2.6 | — |
| Jun Yoon | Option | 413,445 | 7.02 | — |
| Raymond Stevens | Option | 466,687 | 5 | — |
| Raymond Stevens | Option | 826,890 | 7.02 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Daniel G. WelchIndependent · Board Chair · Compensation · Nominating and Corporate Governance (Chair) | $241,500 | $0 | $290,025 | $0 | $0 | $531,525 |
| Sharon TetlowIndependent · Audit (Chair) · Nominating and Corporate Governance | 70,000 | 0 | 290,025 | 0 | 0 | 360,025 |
| Ted W. Love, M.DIndependent · Compensation (Chair) · Research & Development | 67,500 | 0 | 290,025 | 0 | 0 | 357,525 |
| Joanne Waldstreicher, M.DIndependent · Nominating and Corporate Governance · Research & Development (Chair) | 65,000 | 0 | 290,025 | 0 | 0 | 355,025 |
| Eric DobmeierIndependent · Audit · Compensation | 62,500 | 0 | 290,025 | 0 | 0 | 352,525 |
| Angus C. RussellIndependent · Audit | 55,000 | 0 | 239,806 | 0 | 0 | 294,806 |
| Raymond Stevens, Ph.DEmployee director · Research & Development | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $561,500 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $561,500 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Structure Therapeutics as a peer
Companies that benchmark against GPCR
10 companies name GPCR as a compensation peer
The list of companies that name GPCR as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Element | 2025 | Benjamin H. Gliklich | $1,087,500 | $23,688,894 | $0 | $1,520,947 | $26,480,462 |
| 2 | Structure Therapeutics Inc. | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Structure Therapeutics Inc. | 125% | Options 67 · RSU 33 | No | Aon |
| Element | 126% | PRSU 67 · RSU 33 | No | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-17 | 158,547,441 | 6,187,647 | 212,691 | 96.24% | Passed |
| 2025 | 2025-06-23 | 115,026,066 | 19,231,338 | 101,028 | 85.68% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-17 | 96.24%a |
| 2025 | 2025-06-23 | 85.68%b |
a. Approved under the standard stated in the filing — “Abstentions will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.
b. Approved under the standard stated in the filing — “If final voting results are not available to us in time to file a Form 8-K within four business days after the Annual General Meeting, we intend to file a Form 8-K t Abstentions will be counted for the purpose of determining the presence or absence of a quorum, but will not be counted for the purpose of determining the number of votes cast on a given proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 29 : 1 |
|---|---|
| CEO total compensation | $8,429,887 |
| Median employee compensation | $293,807 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Sharon Tetlow | Director | 2026-06-17 | A | 39,453 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Dobmeier | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joanne Waldstreicher | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Angus C. Russell | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel G. Welch | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | D | 23,634 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | D | 7,878 | 49 | 386,646 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | A | 7,878 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | D | 23,634 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | A | 23,634 | 0 | 8,036 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | D | 1,600 | 52 | 82,734 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | D | 23,634 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | D | 23,634 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | A | 23,634 | 0 | 8,036 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | D | 6,278 | 51 | 318,895 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | A | 7,878 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| FMR LLC | Greater-than-10% holder | 2026-07-22 | D | 16,085 | 50 | 805,376 | Derivative, Class A Common | Form 4 ↗ |
| FMR LLC | Greater-than-10% holder | 2026-07-22 | D | 1,367 | 50 | 68,446 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | D | 839 | 50 | 41,974 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | D | 3,100 | 49 | 152,786 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | A | 3,939 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | D | 11,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | D | 11,817 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | A | 11,817 | 0 | 4,018 | Common | Form 4 ↗ |
| John Joseph Berrios | Chief Commercial Officer | 2026-08-06 | A | 140,766 | 0 | 0 | Common | Form 4 ↗ |
| John Joseph Berrios | Chief Commercial Officer | 2026-08-06 | A | 174,612 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | A | 3,939 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 11,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | A | 11,817 | 0 | 4,018 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 400 | 55 | 22,020 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 519 | 54 | 28,128 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 3,020 | 53 | 160,462 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 11,817 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 4,539 | 47 | 214,254 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | A | 5,939 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | A | 17,817 | 0 | 6,058 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 1,300 | 46 | 59,623 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-09-01 | — | 100 | — | ~4,783 | 1 insider, 1 accrual row | ||
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 17,817 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 17,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Blai Coll | Chief Medical Officer | 2026-09-18 | D | 10,626 | 12 | 124,005 | Common | Form 4 ↗ |
| Blai Coll | Chief Medical Officer | 2026-09-21 | D | 4,008 | 36 | 144,873 | Derivative, Class A Common | Form 4 ↗ |
| Blai Coll | Chief Medical Officer | 2026-09-21 | A | 4,008 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Blai Coll | Chief Medical Officer | 2026-09-21 | D | 12,024 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
View all 45 transactions
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Sharon Tetlow | Director | 2026-06-17 | A | 39,453 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Dobmeier | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joanne Waldstreicher | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Angus C. Russell | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Daniel G. Welch | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Ted W. Love | Director | 2026-06-17 | A | 39,453 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | D | 23,634 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | D | 7,878 | 49 | 386,646 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | A | 7,878 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | D | 23,634 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-06-25 | A | 23,634 | 0 | 8,036 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | D | 1,600 | 52 | 82,734 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | D | 23,634 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | D | 23,634 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | A | 23,634 | 0 | 8,036 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | D | 6,278 | 51 | 318,895 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-07-14 | A | 7,878 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| FMR LLC | Greater-than-10% holder | 2026-07-22 | D | 16,085 | 50 | 805,376 | Derivative, Class A Common | Form 4 ↗ |
| FMR LLC | Greater-than-10% holder | 2026-07-22 | D | 1,367 | 50 | 68,446 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | D | 839 | 50 | 41,974 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | D | 3,100 | 49 | 152,786 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | A | 3,939 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | D | 11,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | D | 11,817 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-04 | A | 11,817 | 0 | 4,018 | Common | Form 4 ↗ |
| John Joseph Berrios | Chief Commercial Officer | 2026-08-06 | A | 140,766 | 0 | 0 | Common | Form 4 ↗ |
| John Joseph Berrios | Chief Commercial Officer | 2026-08-06 | A | 174,612 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | A | 3,939 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 11,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | A | 11,817 | 0 | 4,018 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 400 | 55 | 22,020 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 519 | 54 | 28,128 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 3,020 | 53 | 160,462 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-08-18 | D | 11,817 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 4,539 | 47 | 214,254 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | A | 5,939 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | A | 17,817 | 0 | 6,058 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 1,300 | 46 | 59,623 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 100 | 48 | 4,783 | Derivative, Class A Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 17,817 | 0 | 0 | Common | Form 4 ↗ |
| Xichen Lin | Chief Scientific Officer | 2026-09-01 | D | 17,817 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Blai Coll | Chief Medical Officer | 2026-09-18 | D | 10,626 | 12 | 124,005 | Common | Form 4 ↗ |
| Blai Coll | Chief Medical Officer | 2026-09-21 | D | 4,008 | 36 | 144,873 | Derivative, Class A Common | Form 4 ↗ |
| Blai Coll | Chief Medical Officer | 2026-09-21 | A | 4,008 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Blai Coll | Chief Medical Officer | 2026-09-21 | D | 12,024 | 0 | 0 | Common | Form 4 ↗ |
Sources (75 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Raymond Stevens. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table” · page 43. As printed: 8,429,887. View filing ↗
- Section 01, Jun Yoon. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 4,467,595. View filing ↗
- Section 01, Blai Coll. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 3,246,947. View filing ↗
- Section 01, Xichen Lin. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 2,480,709. View filing ↗
- Section 01, Yingli Ma. DEF 14A, filed 2026-04-23. Section “Summary Compensation Table”. As printed: 1,998,882. View filing ↗
- Section 03, Blai Coll OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jun Yoon OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Jun Yoon RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Xichen Lin RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Raymond Stevens RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Xichen Lin OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Blai Coll RSU. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Raymond Stevens OPTION. DEF 14A, filed 2026-04-23. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Yingli Ma RSU. DEF 14A, filed 2026-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Yingli Ma OPTION. DEF 14A, filed 2026-04-23. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-23. Section “CEO Pay Ratio”. As printed: 29 : 1. View filing ↗
- Section 08, Daniel G. Welch. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 531,525. View filing ↗
- Section 08, Sharon Tetlow. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 360,025. View filing ↗
- Section 08, Ted W. Love, M.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 357,525. View filing ↗
- Section 08, Joanne Waldstreicher, M.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 355,025. View filing ↗
- Section 08, Eric Dobmeier. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 352,525. View filing ↗
- Section 08, Angus C. Russell. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 294,806. View filing ↗
- Section 08, Raymond Stevens, Ph.D. DEF 14A, filed 2026-04-23. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Sharon Tetlow 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Eric Dobmeier 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joanne Waldstreicher 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Angus C. Russell 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Daniel G. Welch 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Ted W. Love 2026-06-17. Form 4, filed 2026-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-06-25. Form 4, filed 2026-06-29. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-07-14. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-07-14. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-07-14. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-07-14. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-07-14. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-07-14. Form 4, filed 2026-07-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, FMR LLC 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, FMR LLC 2026-07-22. Form 4, filed 2026-07-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-04. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Joseph Berrios 2026-08-06. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, John Joseph Berrios 2026-08-06. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-08-18. Form 4, filed 2026-08-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Xichen Lin 2026-09-01. Form 4, filed 2026-09-02. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Blai Coll 2026-09-18. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Blai Coll 2026-09-21. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Blai Coll 2026-09-21. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Blai Coll 2026-09-21. Form 4, filed 2026-09-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-18. Item 5.07 · say-on-pay result. As reported: 96.24% (votes for as printed: 158,547,441). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-25. Item 5.07 · say-on-pay result. As reported: 85.68% (votes for as printed: 115,026,066). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 561,500 + equity 0 + all other 0 = 561,500, summed across the director compensation table rows.
- Element, Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Element's own proxy. As printed: 26,480,462. View filing ↗
- Structure Therapeutics Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Structure Therapeutics Inc.'s own proxy. As printed: 8,429,887. View filing ↗